This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Greinacher, A. Articles by Lubenow, N. Search for Related Content PubMed PubMed Citation Articles by Greinacher, A. Articles by Lubenow, N. Related Collections Cardiovascular Pharmacology Acute coronary syndromes Anticoagulants Platelets

(Circulation. 2001;103:1479.)
© 2001 American Heart Association, Inc.

Cardiovascular Drugs

Recombinant Hirudin in Clinical Practice

Focus on Lepirudin

Andreas Greinacher, MD; Norbert Lubenow, MD

From the Institute for Immunology and Transfusion Medicine, Ernst-Moritz-Arndt-University Greifswald, Greifswald, Germany.

Correspondence to Prof Dr A. Greinacher, Ernst-Moritz-Arndt-Universität, Institut für Immunologie und Transfusionsmedizin, Klinikum/Sauerbruchstrasse, 17489 Greifswald, Germany.

Abstract—Clinical applications for recombinant hirudins have been investigated for the past 10 years. The first indication for which a hirudin—lepirudin—has been approved is treatment of heparin-induced thrombocytopenia (HIT). Also, the recently completed trials for use of lepirudin in unstable angina indicate a potentially new indication. This review describes pharmacology and clinical applications of lepirudin with an emphasis on HIT and unstable angina. An overview of usage of lepirudin in acute coronary syndromes is given, as well as a summary of rare indications for lepirudin, such as extracorporeal circulation, for which comprehensive data are lacking.

Key Words: recombinant hirudin • platelets • thrombosis • cardiovascular diseases • heparin

This article has been cited by other articles:

				E. Shantsila, G. Y. H. Lip, and B. H. Chong Heparin-Induced Thrombocytopenia: A Contemporary Clinical Approach to Diagnosis and Management Chest, June 1, 2009; 135(6): 1651 - 1664. [Abstract] [Full Text] [PDF]

				I. Apostolidou, M. F. Sweeney, E. Missov, L. D. Joyce, R. John, and R. C. Prielipp Acute Left Atrial Thrombus After Recombinant Factor VIIa Administration During Left Ventricular Assist Device Implantation in a Patient with Heparin-Induced Thrombocytopenia Anesth. Analg., February 1, 2008; 106(2): 404 - 408. [Abstract] [Full Text] [PDF]

				J. Martchenke, M. F. D. Pate, M. Cruz, and S. Phromsivarak What is the incidence of heparin-induced thrombocytopenia (HIT) in children? Crit. Care Nurse, February 1, 2004; 24(1): 66 - 67. [Full Text] [PDF]

				P. A Arpino and R. K Hallisey Effect of Renal Function on the Pharmacodynamics of Argatroban Ann. Pharmacother., January 1, 2004; 38(1): 25 - 29. [Abstract] [Full Text] [PDF]

				E. A Nutescu and A. K Wittkowsky Direct Thrombin Inhibitors for Anticoagulation Ann. Pharmacother., January 1, 2004; 38(1): 99 - 109. [Abstract] [Full Text] [PDF]

				T. E. Warkentin and A. Greinacher Heparin-induced thrombocytopenia and cardiac surgery Ann. Thorac. Surg., December 1, 2003; 76(6): 2121 - 2131. [Abstract] [Full Text] [PDF]

				A. Greinacher, N. Lubenow, and P. Eichler Anaphylactic and Anaphylactoid Reactions Associated With Lepirudin in Patients With Heparin-Induced Thrombocytopenia Circulation, October 28, 2003; 108(17): 2062 - 2065. [Abstract] [Full Text] [PDF]

				R. Colognato, J. R. Slupsky, M. Jendrach, L. Burysek, T. Syrovets, and T. Simmet Differential expression and regulation of protease-activated receptors in human peripheral monocytes and monocyte-derived antigen-presenting cells Blood, October 1, 2003; 102(7): 2645 - 2652. [Abstract] [Full Text] [PDF]

				S. M. Bates and J. I. Weitz Emerging Anticoagulant Drugs Arterioscler Thromb Vasc Biol, September 1, 2003; 23(9): 1491 - 1500. [Abstract] [Full Text] [PDF]

				T. E. Warkentin and A. Greinacher Heparin-induced thrombocytopenia and cardiac surgery Ann. Thorac. Surg., August 1, 2003; 76(2): 638 - 648. [Abstract] [Full Text] [PDF]

				N. R. Bijsterveld, A. H. Moons, S. M. Boekholdt, B. E. van Aken, H. Fennema, R. J.G. Peters, J. C.M. Meijers, H. R. Buller, and M. Levi Ability of Recombinant Factor VIIa to Reverse the Anticoagulant Effect of the Pentasaccharide Fondaparinux in Healthy Volunteers Circulation, November 12, 2002; 106(20): 2550 - 2554. [Abstract] [Full Text] [PDF]

				N. Lubenow, R. Kempf, A. Eichner, P. Eichler, L. E. Carlsson, and A. Greinacher Heparin-Induced Thrombocytopenia* : Temporal Pattern of Thrombocytopenia in Relation to Initial Use or Reexposure to Heparin Chest, July 1, 2002; 122(1): 37 - 42. [Abstract] [Full Text] [PDF]

				R. L. Bush, P. H. Lin, and A. B. Lumsden Image of the Month Arch Surg, February 1, 2002; 137(2): 221 - 222. [Full Text] [PDF]

				H. Mehta and B. J. Meyer r-Hirudin for percutaneous coronary interventions--time to reconsider? Eur. Heart J., January 2, 2002; 23(2): 95 - 97. [Full Text] [PDF]

				D. E Newby and K. A A Fox Unstable angina: the first 48 hours and later in-hospital management Br. Med. Bull., October 1, 2001; 59(1): 69 - 87. [Abstract] [Full Text] [PDF]